HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery

October 13, 2022

https://www.globenewswire.com/news-release/2022/10/12/2533360/34580/en/HTG-Provides-Update-on-Third-Quarter-Progress-Toward-Its-Transcriptome-Informed-Approach-to-Drug-Discovery.html

TUCSON, Ariz., Oct. 12, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, completed its planned milestones for the third quarter of 2022, further advancing its transcriptome-informed approach to drug design and discovery utilizing the company’s proprietary HTG EdgeSeq technology.

Read more at globenewswire.com

Related news for (HTGM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.